explore -WSS

explore

author：comprehensive 2025-09-02 22:24:17 - browse：4

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： New rules on organ donation and transplantation 'will bring chaos'

hotspot

WSS

7 of the most gruesome medical devices in history

Court strikes down limits on filming of police in Arizona

Feds fine Medicare Advantage plans for overcharging members

White House launches permanent pandemic office

HIPAA doesn't protect reproductive records from prosecutors

A double vaccine crisis is endangering millions of children

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Cancer drug shortages should be causing more outrage

Why an extreme heat and wildfire smoke combination can be so dangerous

Medical records are filled with copy

CDC advisory panel says seniors 'may' get RSV vaccine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Russian special forces kill a gunman who broke into a private house near Moscow

New air purifier tech could be key to improving indoor air quality

FDA panel gives mixed vote on blood pressure devices

Walensky prepares to leave CDC — and Congress — behind

Departing Stanford president retracts two papers

Wikipedia

Why more medical students aren't specializing in primary care

How to make Best Hospitals ratings actually useful for patients

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Organ transplantation is at a crossroads. Major reform is needed

How artificial intelligence is being used to detect, treat cancer

Body of missing toddler recovered in Delaware River days after flood: Police

leisure time

knowledge

hotspot

leisure time